(-0.07%) 5 474.75 points
(-0.11%) 38 776 points
(-0.03%) 19 916 points
(0.17%) $80.47
(1.26%) $2.82
(0.19%) $2 333.40
(-0.26%) $29.32
(-0.22%) $968.80
(0.00%) $0.932
(-0.21%) $10.63
(0.04%) $0.787
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas...
Stats | |
---|---|
Šios dienos apimtis | 29 022 |
Vidutinė apimtis | 0 |
Rinkos kapitalizacija | 789.42M |
EPS | $-0.290 ( Q1 | 2024-05-13 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.600 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0460 (2.43%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-08 | Scheessele William John | Buy | 276 000 | Stock Options (right to buy) |
2023-12-08 | Prichard Heather Ledbetter | Buy | 290 000 | Stock Options (right to buy) |
2023-12-11 | Prichard Heather Ledbetter | Buy | 525 | Stock Options (right to buy) |
2023-12-08 | Parikh Shamik J | Buy | 283 000 | Stock Options (right to buy) |
2023-12-08 | Cao Yang | Buy | 210 000 | Stock Options (right to buy) |
INSIDER POWER |
---|
-73.77 |
Last 96 transactions |
Buy: 5 191 317 | Sell: 41 628 241 |
Humacyte, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Humacyte, Inc. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-7.72M (0.00 %) |
EPS: | $-1.070 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-7.72M (0.00 %) |
EPS: | $-1.070 |
FY | 2022 |
Pajamos: | $1.57M |
Bruto pelnas: | $-6.69M (-427.48 %) |
EPS: | $0.620 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.000660 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Humacyte, Inc.
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.